This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Buxton, D. B. Search for Related Content PubMed PubMed Citation Articles by Buxton, D. B. Related Collections Cardiovascular Pharmacology Cardiovascular imaging agents/Techniques AHA Statements and Guidelines Other Treatment Other diagnostic testing

(Circulation. 2003;108:2737.)
© 2003 American Heart Association, Inc.

Special Report

Recommendations of the National Heart, Lung, and Blood Institute Nanotechnology Working Group

Denis B. Buxton, PhD; Stephen C. Lee, PhD; Samuel A. Wickline, MD; Mauro Ferrari, PhD, for the Working Group Members

From the Division of Heart and Vascular Diseases (D.B.B.), National Heart, Lung, and Blood Institute, Bethesda, Md; Biomedical Engineering Center (S.C.L., M.F.), Ohio State University, Columbus, Ohio; and Washington University School of Medicine (S.A.W.), St Louis, Mo.

Correspondence to Denis Buxton, PhD, 6701 Rockledge Dr, Bethesda, MD 20892-7940. E-mail db225a{at}nih.gov

Recent rapid advances in nanotechnology and nanoscience offer a wealth of new opportunities for diagnosis and therapy of cardiovascular, pulmonary, and hematologic diseases and sleep disorders. To review the challenges and opportunities offered by these nascent fields, the National Heart, Lung, and Blood Institute convened a Working Group on Nanotechnology. Working Group participants discussed the various aspects of nanotechnology and its applications to heart, lung, blood, and sleep (HLBS) diseases. This report summarizes their discussions according to scientific opportunities, perceived needs and barriers, specific disease examples, and recommendations on facilitating research in the field. An overarching recommendation of the Working Group was to focus on translational applications of nanotechnology to solve clinical problems. The Working Group recommended the creation of multidisciplinary research centers capable of developing applications of nanotechnology and nanoscience to HLBS research and medicine. Centers would also disseminate technology, materials, and resources and train new investigators. Individual investigators outside these centers should be encouraged to conduct research on the application of nanotechnology to biological and clinical problems. Pilot programs and developmental research are needed to attract new investigators and to stimulate creative, high-impact research. Finally, encouragement of small businesses to develop nanotechnology-based approaches to clinical problems was considered important.

Key Words: nanotechnology • cardiovascular diseases • lung • blood diseases • sleep

This article has been cited by other articles:

				J. W. Card, D. C. Zeldin, J. C. Bonner, and E. R. Nestmann Pulmonary applications and toxicity of engineered nanoparticles Am J Physiol Lung Cell Mol Physiol, September 1, 2008; 295(3): L400 - L411. [Abstract] [Full Text] [PDF]

				S. A. Wickline, A. M. Neubauer, P. Winter, S. Caruthers, and G. Lanza Applications of Nanotechnology to Atherosclerosis, Thrombosis, and Vascular Biology Arterioscler. Thromb. Vasc. Biol., March 1, 2006; 26(3): 435 - 441. [Abstract] [Full Text] [PDF]

				T. Eschenhagen and W. H. Zimmermann Engineering Myocardial Tissue Circ. Res., December 9, 2005; 97(12): 1220 - 1231. [Abstract] [Full Text] [PDF]

				S. A. Ross, P. R. Srinivas, A. J. Clifford, S. C. Lee, M. A. Philbert, and R. L. Hettich New Technologies for Nutrition Research J. Nutr., March 1, 2004; 134(3): 681 - 685. [Abstract] [Full Text] [PDF]